The nomination committee’s proposal of board of directors in ADDvise Group AB (publ) - Regulatory information

23-02-2021   Regulatory press release

To the annual general Meeting (AGM) of ADDvise Group AB (publ) on 23 April 2021, the nomination committee has decided to propose the re-election of the current board members Rikard Akhtarzand, Fredrik Celsing, Staffan Torstensson and Erland Pontusson as members of the board of directors. In addition, the nomination committee proposes the election of Johanne Louise Brændgaard. It is proposed that Staffan Torstensson is re-elected chairman of the board of directors.

Johanne Louise Brændgaard has a master’s degree in international business economics from Aalborg University, Denmark. Johanne Louise Brændgaard has extensive experience in global sales, marketing and project managing within the MedTech industry from positions at Cook Medical and Getinge. Johanne Louise Brændgaard is independent in relation to the company, its management, and its largest shareholders.

A presentation of the current members of the board of directors is available on ADDvise Group’s website.

The nomination committee's full proposals to the AGM 2021 will be published in connection with the notice to the AGM 2021.

The nomination committee of ADDvise Group for the AGM 2021 consists of Per-Anders Tammerlöv (chairman of the nomination committee) appointed by Rikard Akhtarzand, shareholder through direct and indirect ownership, Per Åhlgren, shareholder through indirect ownership, Magnus Vahlquist, shareholder through direct and indirect ownership and Staffan Torstensson, chairman of ADDvise Group AB. The members of the nomination committee jointly represent approximately 47 per cent of the votes in the company.  

For further information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at


Latest press releases

ADDvise completes the acquisition of MRC Systems FZE


ADDvise Group AB (publ) (”ADDvise”) has today completed the acquisition of all shares in MRC Systems FZE (”MRC”). The signing of the share purchase agreement has been communicated to the market via a press release on 16 February 2021. The total purchase price amounts to USD 8.00 million, of which USD 4.50 million has been…

ADDvise signs Letter of Intent to acquire Medisuite, LLC


ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Medisuite, LLC (”Medisuite”) regarding an acquisition of 100 percent of the shares in Medisuite. Medisuite is an American online pharmacy that specializes in medication for men’s health. The prescription medication that is marketed by Medisuite is mainly used for treatment of…

ADDvise Group to redeem its outstanding up to SEK 240,000,000 senior secured callable bonds


ADDvise Group AB (publ) (“ADDvise") hereby announces that ADDvise’s up to SEK 240,000,000 senior unsecured callable floating rate bonds with ISIN SE0010298166 (the "Bonds"), will be redeemed in advance in accordance with Clause 8.3 (Voluntary total redemption (call option)) of the terms and conditions of the Bonds. The redemption date will be 18 June 2021.…